Real-life effect of long-acting β₂-agonist withdrawal in patients with controlled step 3 asthma

Ann Allergy Asthma Immunol. 2016 Oct;117(4):430-431. doi: 10.1016/j.anai.2016.07.022. Epub 2016 Aug 9.

Authors

Sunny Jabbal¹, Arvind Manoharan¹, William Anderson¹, Joseph Lipworth², Brian Lipworth¹

Affiliations

¹ Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Scotland, United Kingdom.
² Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Scotland, United Kingdom. Electronic address: b.j.lipworth@dundee.ac.uk.

PMID: 27519578
DOI: 10.1016/j.anai.2016.07.022

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Inhalation
Adrenergic beta-Agonists / therapeutic use*
Adult
Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*
Female
Humans
Male

Substances

Adrenergic beta-Agonists
Anti-Asthmatic Agents